TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Haematopoietic stem cell therapy (Primary) ; Zoledronic acid (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus; Tacrolimus; Thiotepa
- Indications Acute myeloid leukaemia; Bone metastases; Cancer metastases; Ewing's sarcoma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Myeloproliferative disorders; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 06 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 06 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 06 Nov 2024 Status changed from suspended to recruiting.